A RCT Evaluating the Clinical Benefit of a Silver Dressing in the Treatment of Venous Leg Ulcers

Completed · Not applicable

Conditions studied: Wound Heal

In brief

Approximately 178 patients with a venous leg ulcer will be included in the investigation evaluating wound healing. All subjects are randomized to one of two treatment arms with an intervention period of 4 weeks followed by a 8 week standard of care period.

Key facts

Study ID: NCT05923749
Run by: Coloplast A/S
People needed: 180
Starts: 2023-06-29
Expected to finish: 2025-01-29
Last updated by the study team: 2025-05-22

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

Has signed informed consent
Is above 18 years of age or above and has full legal capacity
Has venous leg ulcer (C6 of the CEAP classification) with a duration longer than 4 weeks but no longer than 5 years
Has acceptance of compression bandages
Has a wound at risk of infection based on WAR (wounds at risk of infection) score with score of ≥3 points OR has at least three of the following clinical signs of bacterial contamination based on the Therapeutic index for local infections (TILI) score:
Erythema to surrounding skin
Heat
Oedema, induration or swelling
Spontaneous pain or pressure pain
Stalled wound healing
Increase and/or change of color or smell of exudate
Has wound area of min 1x1 cm and max 10x10 cm
Has wound with depth of max 2 cm
Has wound with medium to high level of exudate (but should not require more than 1 dressing change/day)
Has ankle-brachial pressure (ABI) ≥0.8 AND, for patients with diabetes mellitus, additional biphasic Doppler signal up to the ankle
Ability (assessed by the investigator) and willingness to adhere to a 1-month intervention period
For patients with diabetes, has HbA1c ≤ 10%/≤ 86 mmol/mol, measured within the last 3 months prior to inclusion
Should be able to follow the study protocol with the prescribed cleansing product (NaCl) and dressing

You may not qualify if…

Is pregnant or breastfeeding
Has wounds with exposed tendons, bones, fistulas. Or wounds with cavity, undermined or tunnelling
Has infection requiring antibiotics (also for other reasons than wound infection) OR has received antibiotics within the last 1 week before inclusion
Has been receiving the following medical treatment within the last 4 weeks: immunosup-pression, immunomodulating, cytostatic medi-cation or corticoids (topical except for in the wound, inhalation, and stable systemic treat-ment up to 5 mg per day (stable defined as minimum 4 weeks) is allowed
Has a systemic hematological disease
Has renal insufficiency requiring dialysis
Has advanced heart failure NYHA III/IV
Has a psychiatric illness that inhibits compliance with the study protocol
Has severe congenital immunodeficiency such agammaglobulinemia, severe combined immunodeficiency (SCID)
Has allergy towards silver or other dressing ingredients (including compression therapy)
Has wound with > 50% necrotic tissue
Treatment of wound with an anti-microbial wound dressing within the last 2 weeks

Where it is running

Royal Research, Corp. — Hollywood, Florida, United States
Three Rivers Wound and Research Center — North Port, Florida, United States
Detroit foot and ankle Specialists — Clinton Township, Michigan, United States
SerenaGroup Research Center Omaha — Omaha, Nebraska, United States
Serena Group — Monroeville, Pennsylvania, United States
Dermato-Venerologisk Afd — Copenhagen, Denmark
Wundmanagement Gefäßzentrum Aachen Wundmanagement — Aachen, Germany
Katholisches Klinikum Bochum — Bochum, Germany
Krankenhaus Buchholz und Winsen gemeinnüzige GmbH — Buchholz, Germany
ProDerma — Dülmen, Germany
Universitätsklinikum Erlangen — Erlangen, Germany
Universitätsklinikum Giessen und Marburg GmbH — Giessen, Germany
Pioneer Wound Healing and Lymphedema centres — Eastbourne, United Kingdom

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.